NO942983L - Farmasöytiske sammensetninger - Google Patents

Farmasöytiske sammensetninger

Info

Publication number
NO942983L
NO942983L NO942983A NO942983A NO942983L NO 942983 L NO942983 L NO 942983L NO 942983 A NO942983 A NO 942983A NO 942983 A NO942983 A NO 942983A NO 942983 L NO942983 L NO 942983L
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
stabiliser
interferon
buffer
aqueous solution
Prior art date
Application number
NO942983A
Other languages
English (en)
Other versions
NO315843B1 (no
NO942983D0 (no
Inventor
Nicholas Lowther
John Douglas Allen
Colin Howes
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939316849A external-priority patent/GB9316849D0/en
Priority claimed from GB9405879A external-priority patent/GB9405879D0/en
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO942983D0 publication Critical patent/NO942983D0/no
Publication of NO942983L publication Critical patent/NO942983L/no
Publication of NO315843B1 publication Critical patent/NO315843B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
NO19942983A 1993-08-13 1994-08-12 Stabile vandige sammensetninger inneholdende <alfa>- interferonhybrid NO315843B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939316849A GB9316849D0 (en) 1993-08-13 1993-08-13 Pharmaceutical compositions
GB9405879A GB9405879D0 (en) 1994-03-24 1994-03-24 Pharmaceutical compositions

Publications (3)

Publication Number Publication Date
NO942983D0 NO942983D0 (no) 1994-08-12
NO942983L true NO942983L (no) 1995-02-14
NO315843B1 NO315843B1 (no) 2003-11-03

Family

ID=26303371

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19942983A NO315843B1 (no) 1993-08-13 1994-08-12 Stabile vandige sammensetninger inneholdende <alfa>- interferonhybrid

Country Status (19)

Country Link
US (1) US5609868A (no)
EP (1) EP0641567B1 (no)
JP (1) JP3745395B2 (no)
KR (1) KR100351495B1 (no)
AT (1) ATE190498T1 (no)
AU (1) AU679233B2 (no)
CA (1) CA2129921C (no)
CY (1) CY2230B1 (no)
DE (1) DE69423402T2 (no)
DK (1) DK0641567T3 (no)
ES (1) ES2144034T3 (no)
FI (1) FI111222B (no)
GR (1) GR3033239T3 (no)
HU (1) HU224613B1 (no)
IL (1) IL110566A (no)
NO (1) NO315843B1 (no)
NZ (1) NZ264218A (no)
PT (1) PT641567E (no)
TW (1) TW249202B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102236A1 (en) * 1994-12-08 2002-08-01 Taylor Peter William Liposomal interferon hybrid compositions
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
WO1998028007A1 (en) * 1996-12-24 1998-07-02 Biogen, Inc. Stable liquid interferon formulations
KR19990075253A (ko) * 1998-03-18 1999-10-15 성재갑 약학적으로 안정한 인터페론 제
US6685933B1 (en) 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
ES2167189B1 (es) * 1999-12-17 2003-04-01 Lipotec Sa Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos
JP4129178B2 (ja) 2000-11-07 2008-08-06 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 安定化されたインターフェロン組成物
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
EP1909822B1 (en) * 2005-06-29 2013-09-25 Yeda Research And Development Co., Ltd. Recombinant interferon alpha 2 (ifn alpha 2) mutants

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59196823A (ja) * 1983-04-20 1984-11-08 Sunstar Inc 皮膚および粘膜の真菌症治療用外用剤
US4855238A (en) * 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
NO861139L (no) * 1985-03-25 1986-09-26 Schering Corp Stabilt gamma-interferonpreparat.
US4885166A (en) * 1985-06-11 1989-12-05 Ciba-Geigy Corporation Hybrid interferons
US4847079A (en) * 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
EP0331635A3 (en) * 1988-02-29 1990-02-28 The Board of Regents of the University of Texas System Preparations for treating bladder cancer

Also Published As

Publication number Publication date
US5609868A (en) 1997-03-11
FI111222B (fi) 2003-06-30
JPH07145070A (ja) 1995-06-06
HU9402356D0 (en) 1994-10-28
NO315843B1 (no) 2003-11-03
HUT68692A (en) 1995-07-28
IL110566A (en) 1999-12-22
DK0641567T3 (da) 2000-08-14
DE69423402D1 (de) 2000-04-20
EP0641567B1 (en) 2000-03-15
TW249202B (no) 1995-06-11
CA2129921A1 (en) 1995-02-14
JP3745395B2 (ja) 2006-02-15
EP0641567A1 (en) 1995-03-08
ATE190498T1 (de) 2000-04-15
HU224613B1 (hu) 2005-11-28
DE69423402T2 (de) 2000-08-03
KR950005325A (ko) 1995-03-20
NO942983D0 (no) 1994-08-12
FI943705A (fi) 1995-02-14
GR3033239T3 (en) 2000-09-29
AU6893994A (en) 1995-02-23
NZ264218A (en) 1995-07-26
PT641567E (pt) 2000-08-31
AU679233B2 (en) 1997-06-26
CA2129921C (en) 2006-12-05
ES2144034T3 (es) 2000-06-01
FI943705A0 (fi) 1994-08-10
KR100351495B1 (ko) 2003-02-19
IL110566A0 (en) 1995-01-24
CY2230B1 (en) 2003-04-18

Similar Documents

Publication Publication Date Title
IT1283588B1 (it) Miscela sinergica di agenti stabilizzanti
ES2161220T3 (es) 9-((glicil sustituido)amido)-6-desmetil-6-desoxitetraciclinas como agentes antibioticos.
DK1273299T3 (da) Minoxidilinindeholdende praparater
KR960702830A (ko) 방사선 보호제로서의 N-알킬티오 폴리아민 유도체(N-Alkylthio polyaine derivatives as radioprotective agents)
FI943705A (fi) Farmaseuttiset koostumukset
ZA883444B (no)
ES2146606T3 (es) Metodo para limpiar alfombras.
ATE250021T1 (de) Hydroxycyclopentanone
EA199900888A1 (ru) Противоревматические средства
ES2168355T3 (es) Derivados de bisulfuro de indano-2-mercaptoacetilamida utiles como inhibidores de la encefalinasa.
ES2123728T3 (es) Derivados de pirrolo-pirazina de actividad 5-ht3.
MA23133A1 (fr) Derives d&#39;acide d&#39;acyloxyhexanoique .
ATE249478T1 (de) Harnstoff- und thioharnstoffderivate von antibiotisch wirksamen glykopeptiden
NO842345L (no) Heksahydropyrrolo(2,1-a)isoquinolin-derivater.
ES2195309T3 (es) Derivados de tetrahidrofurano.
ITMI950971A1 (it) Derivati aminotiazolici di cefalosporine aventi attivita&#39; antibatterica
BR0004879A (pt) Composições de borracha contendo um sal dissódico do ácido 3,3&#39;-ditiodipropiÈnico

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees